Stockscreener 앱 받기
23.72
3.22%
0.74
시간 외 거래:
23.72
전일 마감가:
$22.98
열려 있는:
$22.98
하루 거래량:
736.82K
Relative Volume:
1.36
시가총액:
$1.55B
수익:
-
순이익/손실:
$-137.95M
주가수익비율:
-9.403
EPS:
-2.5226
순현금흐름:
$-107.11M
1주 성능:
+9.76%
1개월 성능:
+23.61%
6개월 성능:
+26.10%
1년 성능:
+107.16%
1일 변동 폭
$22.54
$24.00
1주일 범위
$21.08
$24.00
52주 변동 폭
$7.80
$24.00
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
23.72 | 1.50B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 개시 | BofA Securities | Buy |
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Insider sales and option exercises reported for BCAX (NASDAQ: BCAX) - Stock Titan
History Review: Is Bicara Therapeutics Incs growth already priced inOptions Play & Technical Buy Zone Confirmation - baoquankhu1.vn
CEO Moves: How liquid is Bicara Therapeutics Inc stockWeekly Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
BCAX PE Ratio & Valuation, Is BCAX Overvalued - Intellectia AI
Published on: 2026-04-10 20:40:14 - baoquankhu1.vn
Trading Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Bicara Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Australia
Bicara Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
T. Rowe Price lists 10.1% of Bicara Therapeutics (NASDAQ: BCAX) in 13G/A - Stock Titan
Bicara Therapeutics Inc. (BCAX) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month HighHere's Why - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration - Yahoo Finance
Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot - TipRanks
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? - AOL.com
BCAX Technical Analysis & Stock Price Forecast - Intellectia AI
A Look At Bicara Therapeutics (BCAX) Valuation After Analyst Upgrades And Clinical Progress News - Sahm
Bicara Therapeutics Inc. (BCAX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed? - simplywall.st
Bicara Therapeutics Announces Inducement Grant - National Today
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript - MSN
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 By Investing.com - Investing.com South Africa
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - qz.com
Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading - Bitget
Is CareCloud (CCLD) Performing Better Than Other Medical Stocks This Year? - Bitget
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 - Investing.com
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Bicara Therapeutics to rally around 121%? Here are 10 top analyst forecasts for Tuesday - MSN
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement (NASDAQ:BCAX) - Seeking Alpha
BCAX SEC FilingsBicara Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group - MarketBeat
Wells Fargo Maintains Rating on BCAX, Increases Price Target to - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company - MarketBeat
Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
BCAX Receives Updated Price Target from HC Wainwright & Co. | BC - GuruFocus
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
HC Wainwright Increases Bicara Therapeutics (NASDAQ:BCAX) Price Target to $42.00 - MarketBeat
Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress - Investing.com UK
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):